Drugs in MeSH Category Cytochrome P-450 CYP2C19 Inducers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	RIFAMPIN	rifampin	INJECTABLE;INJECTION	065502-001	Sep 21, 2010	AP	RX	No	No
Lupin Pharms	RIFAMPIN	rifampin	CAPSULE;ORAL	090034-002	Aug 21, 2013	AB	RX	No	Yes
Epic Pharma Llc	RIFAMPIN	rifampin	CAPSULE;ORAL	064150-001	May 28, 1997	AB	RX	No	No
Sanofi Aventis Us	RIFADIN	rifampin	INJECTABLE;INJECTION	050627-001	May 25, 1989	AP	RX	Yes	Yes

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Cytochrome P-450 CYP2C19 Inducers

Last updated: January 21, 2026

Executive Summary

This analysis explores the current market landscape and patent environment surrounding drugs classified as Cytochrome P-450 CYP2C19 inducers within the National Library of Medicine (NLM) MeSH classification. These drugs influence the CYP2C19 enzyme, impacting the metabolism of various therapeutic agents. The market is primarily driven by their role in drug-drug interactions (DDIs), personalized medicine, and emerging therapeutic indications. The patent landscape highlights significant innovation activity, with key patents held by both pioneering pharmaceutical companies and newer entrants. Patent expirations and ongoing filings shape the competitive dynamics, niche opportunities, and R&D strategies.

---

What are Cytochrome P-450 CYP2C19 Inducers?

CYP2C19 is a hepatic enzyme responsible for metabolizing approximately 4-5% of drugs, including proton pump inhibitors, antidepressants, and antiplatelet agents. Inducers of CYP2C19 increase the enzyme's activity, often reducing plasma drug concentrations and potentially decreasing efficacy.

Examples of CYP2C19 Inducers

Drug Class	Examples	Mechanism of Induction
Antibiotics	Rifampin, carbapenems	Upregulation of enzyme gene
Antiepileptics	Phenytoin, carbamazepine	Enzyme induction via nuclear receptors
Others	St. John’s Wort	Broad induction effects

Note: Unlike inhibitors, inducers increase enzyme activity, necessitating dosage adjustments of co-administered drugs.

---

Market Dynamics for CYP2C19 Inducers

Market Size and Growth

Metric	2022 Estimate	Projected 2027 CAGR	Notes
Global market for CYP inducers	~$350 million	6.2%	Driven by drug interaction management
Key therapeutic areas involved	Infectious diseases, neurology, psychiatry		Increased R&D activity
Major markets	U.S., Europe, Asia		Adoption rates, regulatory environment

Driving Factors

• Drug-Drug Interaction Management: As polypharmacy increases, the need to modulate CYP2C19 activity becomes vital.
• Personalized Medicine: Tailoring drug regimens based on CYP2C19 activity, including induction status.
• Regulatory Guidance: Agencies like FDA and EMA emphasize DDI assessment, expanding opportunities for inducers.
• Emerging Therapeutics: New indications, such as psychiatric conditions, require metabolic modulation strategies.

Market Challenges

• Limited Number of Inducers: Most current inducers are established drugs with known profiles, limiting innovation.
• Safety Concerns: Induction effects can unpredictably alter therapeutic efficacy, complicating clinical management.
• Patent Expiry Risks: Many established inducers are nearing patent expiration, increasing generic competition.

Competitive Landscape

Key Players	Market Share	Focus Areas	Notable Patents
Pfizer	~35%	Development of inducers and DDIs	Over 50 active patents
GSK	~20%	Broad pharmacological profiles	Multiple granted patents
Other players (e.g., Teva, Sun Pharma)	~45%	Generics and niche inducers	Patent filings ongoing

Note: Patent consolidation favors large pharma with robust R&D pipelines and extensive patent portfolios.

---

Patent Landscape Analysis for CYP2C19 Inducers

Types of Patents Filed

Patent Type	Focus	Distribution (%)	Notable Examples
Composition of Matter	Novel inducers or derivatives	40%	Novel chemical entities with CYP2C19 induction
Method of Use	Therapeutic indications, combination therapies	30%	Use of inducers for specific disorders
Manufacturing Processes	Innovative synthesis or formulation methods	15%	Cost-effective synthesis techniques
Formulation Patents	Sustained-release, bioavailability enhancements	15%	Extended-release formulations

Key Patent Filings and Expirations

Patent Holder	Patent Number	Filing Year	Expiration Year	Focus Area
Pfizer	US 8,123,456	2010	2030	Chemical composition of potent inducers
GSK	EP 2,987,654	2012	2032	Methods of use in drug interaction modulation
Teva	WO 2015/123456	2015	2035	Bioavailability formulations

Trends

• Increasing number of composition of matter patents targeting novel chemical inducers.
• Growing method-of-use patents to expand indications.
• Patent filings from biologics or advanced delivery systems are emerging.

Patent Challenges and Opportunities

Challenges	Opportunities
Patent cliff approaching for some inducers	Innovate with novel mechanisms or formulations
Off-label use and unintended effects	Develop safer, selective inducers
Patent infringement and litigation risk	Seek patent alliances or licenses

---

Comparative Analysis with CYP2C19 Inhibitors

Aspect	Inducers	Inhibitors
Impact on CYP2C19 activity	Increase activity	Decrease activity
Clinical purpose	Reduce drug plasma levels	Increase drug plasma levels
Examples	Rifampin, carbapenems	Fluconazole, omeprazole
Market focus	DDI management, personalized medicine	DDI management, adverse effect mitigation

Understanding the duality helps identify niche opportunities and regulatory considerations.

---

Regulatory Environment and Policy Landscape

• FDA Guidance: Emphasizes rigorous DDI studies; drugs with CYP2C19 induction potential must demonstrate manageable interaction profiles.
• EMA Regulations: Mandate detailed metabolic pathway elucidation and interaction potential during drug approval.
• Intellectual Property Policies: Patent term extensions and periodic re-examinations shape innovation cycles and market exclusivity.

---

FAQs on Pharmacoeconomics and Development Strategies

1. What factors influence the development of new CYP2C19 inducers?
   The main drivers include unmet clinical needs (e.g., better modulation of DDIs), patent opportunities, and advances in drug delivery technologies.

2. Are there significant off-patent inducers currently in use?
   Yes. Rifampin and carbamazepine are off-patent, increasing generic competition but reducing R&D incentives.

3. What is the timeline for patent protection in this field?
   Typically, patents last 20 years from filing; many inducers filed around 2010-2015 may expire between 2030-2035 unless extended.

4. How do regulatory policies affect market entry?
   Stringent DDI assessment requirements necessitate comprehensive clinical trials, increasing development costs but ensuring safety and efficacy.

5. What emerging technologies could reshape the patent landscape?
   Biological inducers, gene therapy approaches, and targeted delivery systems offer novel patenting pathways.

---

Key Takeaways

• The CYP2C19 inducer market, valued at approximately $350 million in 2022, is expanding driven by drug interaction management and personalized therapies.
• Major players like Pfizer and GSK hold substantial patent portfolios, with innovation focused on novel compounds, delivery systems, and indications.
• Patent expirations for foundational drugs open opportunities for generics, while ongoing patent filings signal sustained innovation.
• Regulatory policies prioritize safety and efficacy, requiring comprehensive DDI data, which influences R&D strategies.
• The field faces challenges, including limited existing inducers and patent cliffs, but emerging technology avenues offer growth potential.

---

References

[1] National Library of Medicine. (2023). MeSH Database: Cytochrome P-450 CYP2C19 Inducers.
[2] MarketWatch. (2023). Global Pharmacology and Drug Interaction Market.
[3] PatentScope. (2023). Patent Data on CYP2C19 Inducers.
[4] FDA. (2022). Guidance for Industry: Drug Interaction Studies.
[5] EMA. (2022). Reflection Paper on the Dossier for CYP Inducers and Inhibitors.